1. Home
  2. CTRN vs PRTA Comparison

CTRN vs PRTA Comparison

Compare CTRN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Citi Trends Inc.

CTRN

Citi Trends Inc.

HOLD

Current Price

$63.92

Market Cap

460.5M

ML Signal

HOLD

Logo Prothena Corporation plc

PRTA

Prothena Corporation plc

HOLD

Current Price

$8.69

Market Cap

526.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CTRN
PRTA
Founded
1946
2012
Country
United States
Ireland
Employees
N/A
N/A
Industry
Clothing/Shoe/Accessory Stores
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
460.5M
526.7M
IPO Year
2005
2013

Fundamental Metrics

Financial Performance
Metric
CTRN
PRTA
Price
$63.92
$8.69
Analyst Decision
Strong Buy
Buy
Analyst Count
1
9
Target Price
$52.00
$19.00
AVG Volume (30 Days)
238.4K
604.5K
Earning Date
06-02-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
112.14
N/A
EPS
0.91
0.60
Revenue
$819,962,000.00
$814,000.00
Revenue This Year
$8.81
$1,111.38
Revenue Next Year
$8.35
N/A
P/E Ratio
$70.39
$14.11
Revenue Growth
8.88
N/A
52 Week Low
$28.45
$6.24
52 Week High
$66.38
$11.80

Technical Indicators

Market Signals
Indicator
CTRN
PRTA
Relative Strength Index (RSI) 66.29 42.31
Support Level $42.10 $8.36
Resistance Level $66.38 $10.29
Average True Range (ATR) 2.94 0.45
MACD 0.33 -0.11
Stochastic Oscillator 81.43 30.12

Price Performance

Historical Comparison
CTRN
PRTA

About CTRN Citi Trends Inc.

Citi Trends Inc is a differentiated off-price value retailer known for trendy fashions, great brands and amazing prices. It is the off-price retailer specifically focused on Black customers, delivering the styles, brands, and trends at amazing prices that resonate with its primary and secondary customers. Its product offering is Women's, Men's and Children's apparel, family footwear, accessories and products for the home, with a three-tiered mix of product. At the opening price point, the company offers value-focused basics for its budget-conscious customers.

About PRTA Prothena Corporation plc

Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.

Share on Social Networks: